Implications of Phase 2 Trial Assessing Niraparib in the Treatment of Uterine Serous Carcinoma

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

Pharmacy Times interviewed Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute and associate professor at Zucker School of Medicine in Hofstra/Northwell, on her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

During this interview, Frimer discussed the implications of the phase 2 trial assessing niraparib on the treatment of patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Marina Frimer: So, at this time, we don't have results. However, the study is actively recruiting patients.

Women with uterine serous cancer generally have high rates of recurrence, and the options for treatment at this time at recurrence are limited. Results of this trial may change treatment algorithm to include maintenance therapy with niraparib following platinum-based adjuvant chemotherapy.